Učitavanje...
RAS and BRAF in metastatic colorectal cancer management
The treatment of metastatic colorectal cancer (mCRC) has been further refined with the development of monoclonal antibodies, cetuximab and panitumumab, towards the epidermal growth factor receptor (EGFR). Anti-EGFR therapy has afforded improved survival in those with wild-type RAS mCRC but provides...
Spremljeno u:
| Izdano u: | J Gastrointest Oncol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5056249/ https://ncbi.nlm.nih.gov/pubmed/27747083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.06.12 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|